Project Description:
Traditional hemofiltration systems are limited by low blood flow rates (0.1–0.5 L/min) and instability during rapid solute clearance, resulting in inefficient toxin removal. To address these shortcomings, this project aims to develop a high-flux, high-efficiency hemofiltration system capable of operating at significantly higher blood flow rates. Leveraging the Revaclear 300 Dialyzer, we successfully increased flow rates to 4-5 L/min for enhanced clearance. The system incorporates a 12-filter array, each supporting a flux of 500 mL/min, to distribute a total flow of 4–5 L/min while maintaining filter pressure between 100–150 mmHg—crucial for preserving membrane integrity and preventing fouling. This device is also designed to remove a broader range of toxins, including those previously difficult to eliminate. To validate its performance, we tested the system using creatinine as a model toxin and demonstrated its ability to efficiently filter it from circulation. Our team built on proof-of-concept work by University of Maryland bioengineering students to refine the system for clinical application, marking a key milestone in bringing the technology from bench to bedside. Ultimately, this project has the potential to significantly improve outcomes for critically ill patients by expanding access to more effective extracorporeal detoxification.
